Loading clinical trials...

Using Drug Augmentation to Treat Obsessive Compulsive Disorder Patients Who Did Not Respond to Previous Treatment | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Using Drug Augmentation to Treat Obsessive Compulsive Disorder Patients Who Did Not Respond to Previous Treatment

Pharmacological Augmentation Strategies for Obsessive Compulsive Disorder Patients Non-respondent to First Line Medication Treatment: a Double Blind Placebo Controlled Study

NCT00466609•University of Sao Paulo

View on ClinicalTrials.gov

Summary

This will be a controlled, randomized, double-blind and double-dummy study on the treatment augmentation strategy for obsessive compulsive disorder patients non-respondent to first line pharmacological treatment. The investigators will compare: fluoxetine maintenance at maximum dosage for additional 12 weeks; the association of fluoxetine with quetiapine; and the association of fluoxetine with clomipramine.

Detailed Description

Arm 1: SSRI (Fluoxetine 40mg\* once a day) + Clomipramine 75mg\* once a day. Arm 2: SSRI (Fluoxetine 40mg\* once a day) + Quetiapine 200mg\* once a day. Arm 3: SSRI (Fluoxetine 80mg\* once a day) + Placebo once a day. \*or maximum tolerated dose We hypothesize that quetiapine and clomipramine will be effective augmentation strategies for resistant OCD patients in comparison to placebo.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. OCD diagnosis
•2. YBOCS score ≥ 16 (for patients with both obsessions and compulsions) or ≥ 10 (for patients with only obsessions or compulsions)
•3. Previously signed informed consent to participate in this clinical trial

Exclusion Criteria

•1. Patients with clinical or neurological diseases that may be worsen by the medications included in treatment protocol
•2. Current substance dependence or abuse
•3. Current psychotic symptoms
•4. Current suicide risk
•5. Current pregnancy or intention to get pregnant before the end of the treatment protocol

Locations (1)

Institute of Psychiatry

São Paulo, São Paulo, Brazil

Key Dates

Start Date

May 1, 2007

Primary Completion Date

March 1, 2010

Completion Date

April 1, 2010

Last Updated

October 30, 2017

Enrollment

ACTUAL participants

Conditions

Obsessive Compulsive Disorder

Interventions

Clomipramine (fluoxetine plus clomipramine)

DRUG

Quetiapine (fluoxetine plus quetiapine)

DRUG

Placebo (fluoxetine plus placebo)

DRUG

Precision Analytic Research Methods in OCD

NCT07011901

Obsessive Compulsive Disorder

View study

RECRUITING

Pharmacogenomics of Selective Serotonin Reuptake Inhibitor (SSRI)-Induced Behavioural Activation

NCT06763081

Behavioral ActivationMajor Depressive Disorder+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 30, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Using Drug Augmentation to Treat Obsessive Compulsive Disorder Patients Who Did Not Respond to Previous Treatment

Inclusion Criteria

Exclusion Criteria

Precision Analytic Research Methods in OCD

Pharmacogenomics of Selective Serotonin Reuptake Inhibitor (SSRI)-Induced Behavioural Activation

Brief Cognitive Behaviour Therapy (CBT) for Adolescent OCD in Routine Clinical Practice

Combined Cortical/Subcortical Recording and Stimulation as a Circuit-Oriented Treatment for Obsessive-Compulsive Disorder

NAC for Treatment-Resistant OCD and Other Related Disorders

Assessments of Obsessive-compulsive Symptoms in Patients With Substances Use Disorder